✨ Medicines Distribution Consent
NEW ZEALAND GAZETTE
No. 41
Schedule
| Name and Strength | Form | Name and Address of Manufacturer | Proprietary Name (if any) |
|---|---|---|---|
| Clotrimazole 1% w/w | Powder, topical | Bayer AG., Leverkusen, Germany; Bayer Australia Limited, Mulgrave, Victoria, Australia; and Bayer SpA., Garbagnate, Milanese, Italy | Canesten Broad Spectrum Antifungal Powder |
| Phytomenadione 10 mg/mL | Injection, solution | F Hoffmann-La Roche Limited, Basle, Switzerland | Konakion MM Paediatric |
| Ethinyloestradiol 20 µg, levonorgestrel 100 µg | Tablet, coated | Schering AG., Wedding, Berlin, Germany | Microgynon 20 ED |
Dated this 26th day of March 1999.
GILLIAN GREW, Chief Advisor, Regulation and Safety (acting), pursuant to delegation given by the Minister of Health on the 20th day of February 1997.
go2429
Consent to the Distribution of a New Medicine
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicine set out in the Schedule hereto:
Schedule
| Name and Strength | Form | Name and Address of Manufacturer | Proprietary Name (if any) |
|---|---|---|---|
| Beclomethasone dipropionate 200 µg per metered dose | Inhalation, powder | Orion Corporation, Espoo, Finland | Atomide Easyhaler |
| Oestradiol 0.312 mg/cm² (25 µg/24 hours) | Transdermal patch | 3M Pharmaceuticals, Northridge, California, United States of America | Climara 25 |
| Oestradiol 0.312 mg/cm² (75 µg/24 hours) | Transdermal patch | 3M Pharmaceuticals, Northridge, California, United States of America | Climara 75 |
| Dextromethorphan hydrobromide 1 mg/mL, Ammonium chloride 25 mg/mL, diphenhydramine hydrochloride 2.5 mg/mL | Syrup | PSM Healthcare Limited, Wiri, Auckland | Dextromethorphan Cough Mixture |
| Dextromethorphan hydrobromide 1 mg/mL | Syrup | PSM Healthcare Limited, Wiri, Auckland | Diphenhydramine Cough Mixture |
| Oestradiol hemihydrate 0.312 mg/cm² (25 µg/24 hours) | Transdermal patch | 3M Pharmaceuticals, Northridge, California, United States of America | Femtran 25 |
| Oestradiol hemihydrate 0.312 mg/cm² (75 µg/24 hours) | Transdermal patch | 3M Pharmaceuticals, Northridge, California, United States of America | Femtran 75 |
| Hydrocortisone 1% w/w, miconazole 2% w/w | Cream, topical | Ego Pharmaceuticals Pty Limited, Braeside, Victoria, Australia | Fungocort |
| Opium tincture 1% 16.08 mg/mL, squill oxymel (as EFM oxymel squill 125:1000) 44.4 mg/mL | Linctus | PSM Healthcare Limited, Wiri, Auckland | Gees Linctus |
| Morphine sulphate 10 mg | Capsule, modified release | Faulding Pharmaceuticals, Salisbury, South Australia, Australia | Kapanol |
| Opti-Plus: Pancreatin equivalent to 950 µg tyrosine/min/mL, Opti-Free: Citric acid monohydrate 0.021% w/v, disodium citrate dihydrate 0.56% w/v, sodium chloride 0.516% w/v | Solutions, contact lens | Opti-Plus: Alcon Cusi SA., Alcobendas, Madrid, Spain; Opti-Free: Alcon Cusi SA., Alcobendas, Madrid, Spain; and Alcon Laboratories Inc., Fort Worth, Texas, United States of America | Opti-Free / Opti-Plus Combination Pack |
| Paracetamol 500 mg | Suppository | Rice Steele & Co Limited, Tallaght, Dublin, Eire | Paralink |
| Ranitidine hydrochloride 84 mg (equivalent to 75 mg ranitidine base) | Tablet, film coated | Glaxo Wellcome Operations, Ware, Hertfordshire, United Kingdom; and Glaxo Wellcome SA., Aranda de Duero, Spain | Zantac 75 |
Dated this 26th day of March 1999.
GILLIAN GREW, Chief Advisor, Regulation and Safety (acting), pursuant to delegation given by the Minister of Health on the 20th day of February 1997.
go2430
Next Page →
PDF embedding disabled (Crown copyright)
View this page online at:
VUW Te Waharoa —
NZ Gazette 1999, No 41
NZLII —
NZ Gazette 1999, No 41
✨ LLM interpretation of page content
🏥 Consent to the Distribution of Changed Medicines
🏥 Health & Social Welfare26 March 1999
Medicines Act 1981, Changed Medicines, Distribution Consent
- GILLIAN GREW, Chief Advisor, Regulation and Safety (acting)
🏥 Consent to the Distribution of a New Medicine
🏥 Health & Social Welfare26 March 1999
Medicines Act 1981, New Medicine, Distribution Consent
- GILLIAN GREW, Chief Advisor, Regulation and Safety (acting)